BACKGROUND: The impact of lung cancer screening on smoking behavior is unclear. The aims of this ancillary study of the Prostate Lung Colorectal and Ovarian Cancer Screening Trial were to produce risk prediction models to identify individuals at risk of relapse or continued smoking and to evaluate whether cancer-screening variables affect long-term smoking outcomes. METHODS: Participants completed a baseline questionnaire at trial enrollment and a supplemental questionnaire 4-14 years after enrollment, which assessed several cancer-related variables, including family history of cancer, comorbidities, and tobacco use. Multivariable logistic regression models were used to predict smoking status at completion of the supplemental questionnaire. The models' predictive performances were evaluated by assessing discrimination via the receiver operator characteristic area under the curve (ROC AUC) and calibration. Models were internally validated using bootstrap methods. RESULTS: Of the 31 694 former smokers on the baseline questionnaire, 1042 (3.3%) had relapsed (ie, reported being a current smoker on the supplemental questionnaire). Of the 6807 current smokers on the baseline questionnaire, 4439 (65.2%) reported continued smoking on the supplemental questionnaire. Relapse was associated with multiple demographic, medical, and tobacco-related characteristics. This model had a bootstrap median ROC AUC of 0.862 (95% confidence interval [CI] = 0.858 to 0.866) and a calibration slope of 1.004 (95% CI = 0.978 to 1.029), indicating excellent discrimination and calibration. Predictors of continued smoking also included multiple demographic, medical, and tobacco-related characteristics. This model had an ROC AUC of 0.611 (95% CI = 0.605 to 0.614) and a slope of 1.006 (95% CI = 0.962 to 1.041), indicating modest discrimination. Neither the trial arm nor the lung-screening result was statistically significantly associated with smoking outcomes. CONCLUSION: These models, if validated externally, may have public health utility in identifying individuals at risk for adverse smoking outcomes, who may benefit from relapse prevention and smoking cessation interventions.
RCT Entities:
BACKGROUND: The impact of lung cancer screening on smoking behavior is unclear. The aims of this ancillary study of the Prostate Lung Colorectal and Ovarian Cancer Screening Trial were to produce risk prediction models to identify individuals at risk of relapse or continued smoking and to evaluate whether cancer-screening variables affect long-term smoking outcomes. METHODS:Participants completed a baseline questionnaire at trial enrollment and a supplemental questionnaire 4-14 years after enrollment, which assessed several cancer-related variables, including family history of cancer, comorbidities, and tobacco use. Multivariable logistic regression models were used to predict smoking status at completion of the supplemental questionnaire. The models' predictive performances were evaluated by assessing discrimination via the receiver operator characteristic area under the curve (ROC AUC) and calibration. Models were internally validated using bootstrap methods. RESULTS: Of the 31 694 former smokers on the baseline questionnaire, 1042 (3.3%) had relapsed (ie, reported being a current smoker on the supplemental questionnaire). Of the 6807 current smokers on the baseline questionnaire, 4439 (65.2%) reported continued smoking on the supplemental questionnaire. Relapse was associated with multiple demographic, medical, and tobacco-related characteristics. This model had a bootstrap median ROC AUC of 0.862 (95% confidence interval [CI] = 0.858 to 0.866) and a calibration slope of 1.004 (95% CI = 0.978 to 1.029), indicating excellent discrimination and calibration. Predictors of continued smoking also included multiple demographic, medical, and tobacco-related characteristics. This model had an ROC AUC of 0.611 (95% CI = 0.605 to 0.614) and a slope of 1.006 (95% CI = 0.962 to 1.041), indicating modest discrimination. Neither the trial arm nor the lung-screening result was statistically significantly associated with smoking outcomes. CONCLUSION: These models, if validated externally, may have public health utility in identifying individuals at risk for adverse smoking outcomes, who may benefit from relapse prevention and smoking cessation interventions.
Authors: Matthew M Clark; Lisa Sanderson Cox; James R Jett; Christi A Patten; Darrell R Schroeder; Liza M Nirelli; Kristin Vickers; Richard D Hurt; Stephen J Swensen Journal: Lung Cancer Date: 2004-04 Impact factor: 5.705
Authors: Carlijn M van der Aalst; Harry J de Koning; Karien A M van den Bergh; Marc C Willemsen; Rob J van Klaveren Journal: Lung Cancer Date: 2011-11-04 Impact factor: 5.705
Authors: Carlijn Michelle van der Aalst; Karien Anna Margaretha van den Bergh; Marc Christiaan Willemsen; Henricus Johannes de Koning; Robertus Johannes van Klaveren Journal: Thorax Date: 2010-07 Impact factor: 9.139
Authors: C M van der Aalst; R J van Klaveren; K A M van den Bergh; M C Willemsen; H J de Koning Journal: Eur Respir J Date: 2010-12-09 Impact factor: 16.671
Authors: Cynthia O Townsend; Matthew M Clark; James R Jett; Christi A Patten; Darrell R Schroeder; Liza M Nirelli; Stephen J Swensen; Richard D Hurt Journal: Cancer Date: 2005-05-15 Impact factor: 6.860
Authors: M Bednarek; D Gorecka; J Wielgomas; M Czajkowska-Malinowska; J Regula; G Mieszko-Filipczyk; M Jasionowicz; R Bijata-Bronisz; M Lempicka-Jastrzebska; M Czajkowski; G Przybylski; J Zielinski Journal: Thorax Date: 2006-06-29 Impact factor: 9.139
Authors: Melissa A Clark; Jeremy J Gorelick; JoRean D Sicks; Elyse R Park; Amanda L Graham; David B Abrams; Ilana F Gareen Journal: Nicotine Tob Res Date: 2015-03-06 Impact factor: 4.244
Authors: Martin C Tammemägi; Christine D Berg; Thomas L Riley; Christopher R Cunningham; Kathryn L Taylor Journal: J Natl Cancer Inst Date: 2014-05-28 Impact factor: 13.506
Authors: Shuguang Leng; Joel L Weissfeld; Maria A Picchi; Mindi A Styn; Eric D Claus; Vincent P Clark; Guodong Wu; Cynthia L Thomas; Frank D Gilliland; Jianmin Yuan; Jill M Siegfried; Steven A Belinsky Journal: Int J Mol Epidemiol Genet Date: 2016-06-01
Authors: Kathryn L Taylor; Charlotte J Hagerman; George Luta; Paula G Bellini; Cassandra Stanton; David B Abrams; Jenna A Kramer; Eric Anderson; Shawn Regis; Andrea McKee; Brady McKee; Ray Niaura; Harry Harper; Michael Ramsaier Journal: Lung Cancer Date: 2017-02-15 Impact factor: 5.705
Authors: Kathryn L Taylor; Danielle E Deros; Shelby Fallon; Jennifer Stephens; Emily Kim; Tania Lobo; Kimberly M Davis; George Luta; Jinani Jayasekera; Rafael Meza; Cassandra A Stanton; Raymond S Niaura; David B Abrams; Brady McKee; Judith Howell; Michael Ramsaier; Juan Batlle; Ellen Dornelas; Vicky Parikh; Eric Anderson Journal: Contemp Clin Trials Date: 2019-05-23 Impact factor: 2.226
Authors: Yung-Hung Luo; Lei Luo; Jason A Wampfler; Yi Wang; Dan Liu; Yuh-Min Chen; Alex A Adjei; David E Midthun; Ping Yang Journal: Lancet Oncol Date: 2019-06-26 Impact factor: 41.316
Authors: Andrea K Borondy Kitts; Andrea B McKee; Shawn M Regis; Christoph Wald; Sebastian Flacke; Brady J McKee Journal: J Thorac Dis Date: 2016-07 Impact factor: 2.895